Smith & Nephew Plc (SNN)

$25.04

-0.17

(-0.67%)▲

Market is closed - opens 8 PM, 22 Nov 2024

Performance

  • $24.94
    $25.17
    $25.04
    downward going graph

    0.4%

    Downside

    Day's Volatility :0.91%

    Upside

    0.52%

    downward going graph
  • $23.65
    $31.72
    $25.04
    downward going graph

    5.55%

    Downside

    52 Weeks Volatility :25.44%

    Upside

    21.06%

    downward going graph

Returns

PeriodSmith & Nephew PlcSector (Health Care)Index (Russel 2000)
3 Months
-18.25%
-6.9%
0.0%
6 Months
-2.3%
-1.7%
0.0%
1 Year
-2.49%
10.4%
0.0%
3 Years
-26.24%
8.8%
-24.1%

Highlights

Market Capitalization
11.0B
Book Value
$5.96
Dividend Share
0.375
Dividend Yield
2.98%
Earnings Per Share (EPS)
0.7
PE Ratio
36.01
PEG Ratio
0.42
Wall Street Target Price
32.554
Profit Margin
5.41%
Operating Margin TTM
11.6%
Return On Assets TTM
4.51%
Return On Equity TTM
5.84%
Revenue TTM
5.6B
Revenue Per Share TTM
2.59
Quarterly Revenue Growth YOY
3.4000000000000004%
Gross Profit TTM
3.7B
EBITDA
1.1B
Diluted Eps TTM
0.7
Quarterly Earnings Growth YOY
0.24
EPS Estimate Current Year
1.41
EPS Estimate Next Year
1.71
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    70%Buy
    25%Hold
    4%Sell
Based on 24 Wall street analysts offering stock ratings for Smith & Nephew Plc(by analysts ranked 0 to 5 stars)
Based on 24 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
17
17
17
Hold
6
6
7
Sell
1
1
00

Analyst Forecast

What analysts predicted

Upside of 30.01%

Current $25.04
Target $32.55

Company Financials

FY18Y/Y Change
Revenue
4.9B
↑ 2.92%
Net Income
663.0M
↓ 13.56%
Net Profit Margin
13.52%
↓ 2.58%
FY19Y/Y Change
Revenue
5.1B
↑ 4.77%
Net Income
600.0M
↓ 9.5%
Net Profit Margin
11.68%
↓ 1.84%
FY20Y/Y Change
Revenue
4.6B
↓ 11.25%
Net Income
448.0M
↓ 25.33%
Net Profit Margin
9.82%
↓ 1.86%
FY21Y/Y Change
Revenue
5.2B
↑ 14.3%
Net Income
524.0M
↑ 16.96%
Net Profit Margin
10.05%
↑ 0.23%
FY22Y/Y Change
Revenue
5.2B
↑ 0.06%
Net Income
223.0M
↓ 57.44%
Net Profit Margin
4.28%
↓ 5.77%
FY23Y/Y Change
Revenue
5.5B
↑ 6.4%
Net Income
263.0M
↑ 17.94%
Net Profit Margin
4.74%
↑ 0.46%
Q3 FY22Q/Q Change
Revenue
1.3B
↓ 49.71%
Net Income
23.0M
↓ 87.01%
Net Profit Margin
1.76%
↓ 5.05%
Q4 FY22Q/Q Change
Revenue
2.7B
↑ 109.79%
Net Income
48.3M
↑ 109.79%
Net Profit Margin
1.76%
↑ 0.0%
Q1 FY23Q/Q Change
Revenue
1.4B
↓ 50.16%
Net Income
86.0M
↑ 78.23%
Net Profit Margin
6.29%
↑ 4.53%
Q2 FY23Q/Q Change
Revenue
2.7B
↑ 100.0%
Net Income
172.0M
↑ 100.0%
Net Profit Margin
6.29%
↑ 0.0%
Q4 FY23Q/Q Change
Revenue
2.8B
↑ 2.14%
Net Income
90.3M
↓ 47.51%
Net Profit Margin
3.23%
↓ 3.06%
Q2 FY24Q/Q Change
Revenue
2.8B
↑ 1.23%
Net Income
214.0M
↑ 137.05%
Net Profit Margin
7.57%
↑ 4.34%
FY18Y/Y Change
Total Assets
8.1B
↑ 2.45%
Total Liabilities
3.2B
↓ 1.15%
FY19Y/Y Change
Total Assets
9.3B
↑ 15.39%
Total Liabilities
4.2B
↑ 30.55%
FY20Y/Y Change
Total Assets
11.0B
↑ 18.42%
Total Liabilities
5.7B
↑ 37.88%
FY21Y/Y Change
Total Assets
10.9B
↓ 0.84%
Total Liabilities
5.4B
↓ 6.65%
FY22Y/Y Change
Total Assets
10.0B
↓ 8.74%
Total Liabilities
4.7B
↓ 12.05%
FY23Y/Y Change
Total Assets
10.0B
↑ 0.21%
Total Liabilities
4.8B
↑ 1.34%
Q3 FY22Q/Q Change
Total Assets
10.1B
↑ 0.0%
Total Liabilities
4.7B
↓ 0.06%
Q4 FY22Q/Q Change
Total Assets
10.0B
↓ 1.38%
Total Liabilities
4.7B
↑ 0.0%
Q1 FY23Q/Q Change
Total Assets
10.0B
↑ 0.0%
Total Liabilities
4.6B
↓ 2.04%
Q2 FY23Q/Q Change
Total Assets
9.8B
↓ 1.22%
Total Liabilities
4.6B
↑ 0.0%
Q4 FY23Q/Q Change
Total Assets
10.0B
↑ 1.45%
Total Liabilities
4.8B
↑ 3.45%
Q2 FY24Q/Q Change
Total Assets
10.5B
↑ 5.56%
Total Liabilities
5.3B
↑ 11.89%
FY18Y/Y Change
Operating Cash Flow
931.0M
↓ 14.59%
Investing Cash Flow
-378.0M
↓ 30.39%
Financing Cash Flow
-371.0M
↓ 14.52%
FY19Y/Y Change
Operating Cash Flow
1.2B
↑ 25.46%
Investing Cash Flow
-1.3B
↑ 230.95%
Financing Cash Flow
7.0M
↓ 101.89%
FY20Y/Y Change
Operating Cash Flow
935.0M
↓ 19.95%
Investing Cash Flow
-606.0M
↓ 51.56%
Financing Cash Flow
1.2B
↑ 16528.57%
FY21Y/Y Change
Operating Cash Flow
877.0M
↓ 6.2%
Investing Cash Flow
-691.0M
↑ 14.03%
Financing Cash Flow
-645.0M
↓ 155.41%
FY22Y/Y Change
Operating Cash Flow
468.0M
↓ 46.64%
Investing Cash Flow
-472.0M
↓ 31.69%
Financing Cash Flow
-926.0M
↑ 43.57%
Q3 FY22Q/Q Change
Operating Cash Flow
130.5M
↓ 36.96%
Investing Cash Flow
-102.0M
↓ 23.88%
Financing Cash Flow
-111.0M
↓ 84.23%
Q4 FY22Q/Q Change
Operating Cash Flow
130.5M
↑ 0.0%
Investing Cash Flow
-472.0M
↑ 362.75%
Financing Cash Flow
-111.0M
↑ 0.0%
Q1 FY23Q/Q Change
Operating Cash Flow
56.5M
↓ 56.7%
Investing Cash Flow
-91.0M
↓ 80.72%
Financing Cash Flow
-43.0M
↓ 61.26%
Q2 FY23Q/Q Change
Operating Cash Flow
56.5M
↑ 0.0%
Investing Cash Flow
-182.0M
↑ 100.0%
Financing Cash Flow
-43.0M
↑ 0.0%

Technicals Summary

Sell

Neutral

Buy

Smith & Nephew Plc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Smith & Nephew Plc
Smith & Nephew Plc
-14.95%
-2.3%
-2.49%
-26.24%
-43.18%
Stryker Corporation
Stryker Corporation
6.59%
16.31%
32.68%
49.88%
93.53%
Boston Scientific Corp.
Boston Scientific Corp.
3.97%
21.4%
65.07%
124.82%
118.64%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
1.65%
-21.98%
4.95%
-38.71%
-12.32%
Abbott Laboratories
Abbott Laboratories
0.98%
11.87%
14.18%
-6.39%
40.03%
Medtronic Plc
Medtronic Plc
-7.0%
-1.19%
8.13%
-27.5%
-23.53%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Smith & Nephew Plc
Smith & Nephew Plc
36.01
36.01
0.42
1.41
0.06
0.05
0.03
5.96
Stryker Corporation
Stryker Corporation
41.34
41.34
2.69
12.05
0.19
0.07
0.01
52.86
Boston Scientific Corp.
Boston Scientific Corp.
74.52
74.52
1.64
2.46
0.09
0.05
NA
14.05
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
27.17
27.17
6.38
2.53
0.19
0.11
NA
16.18
Abbott Laboratories
Abbott Laboratories
35.56
35.56
2.25
4.68
0.15
0.06
0.02
22.94
Medtronic Plc
Medtronic Plc
29.55
29.55
1.63
5.2
0.08
0.04
0.03
37.39
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Smith & Nephew Plc
Smith & Nephew Plc
Buy
$11.0B
-43.18%
36.01
5.41%
Stryker Corporation
Stryker Corporation
Buy
$147.0B
93.53%
41.34
16.34%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$132.9B
118.64%
74.52
11.26%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$41.5B
-12.32%
27.17
65.86%
Abbott Laboratories
Abbott Laboratories
Buy
$203.2B
40.03%
35.56
13.99%
Medtronic Plc
Medtronic Plc
Buy
$110.3B
-23.53%
29.55
12.06%

Insights on Smith & Nephew Plc

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 1.36B → 2.82B (in $), with an average increase of 17.8% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, 90.27M → 214.0M (in $), with an average increase of 57.8% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 65.1% return, outperforming this stock by 67.6%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 124.8% return, outperforming this stock by 151.0%

Institutional Holdings

  • Fiduciary Management, Inc. of Milwaukee

    1.00%

  • Barrow Hanley Mewhinney & Strauss LLC

    0.91%

  • Scharf Investments

    0.67%

  • Morgan Stanley - Brokerage Accounts

    0.65%

  • TPG GP A, LLC

    0.48%

  • Goldman Sachs Group Inc

    0.35%

Corporate Announcements

  • Smith & Nephew Plc Dividends September,2024

    In the quarter ending September,2024. Smith & Nephew Plc has declared dividend of $0.46

    Read More

Company Information

Smith & Nephew plc, also known as Smith+Nephew, is a British multinational medical equipment manufacturing company headquartered in Watford, England.

Organization
Smith & Nephew Plc
Employees
18000
CEO
Dr. Deepak S. Nath Ph.D.
Industry
Health Technology

FAQs